Comparative Pharmacology
Head-to-head clinical analysis: AVOPEF versus DEPOCYT.
Peer-Reviewed Evidence
Head-to-head clinical analysis: AVOPEF versus DEPOCYT.
AVOPEF vs DEPOCYT
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Avopef is a synthetic peptide analog that acts as a selective antagonist of the nociceptin/orphanin FQ (N/OFQ) receptor (NOP), modulating pain pathways and stress responses. It also exhibits partial agonist activity at mu-opioid receptors, contributing to its analgesic and anxiolytic effects.
Cytarabine is a nucleoside analog that inhibits DNA polymerase, leading to termination of DNA chain elongation and cell death in the S phase of the cell cycle.
Adults: 400 mg intravenously every 8 hours for 7-14 days.
50 mg intrathecally via lumbar puncture or intraventricularly via Ommaya reservoir on days 1, 15, 29, 43, 57, 71, 85, and 99 for induction; followed by consolidation and maintenance doses. Administer with dexamethasone 4 mg PO/IV twice daily for 5 days starting on the day of DepoCyt injection.
None Documented
None Documented
Terminal elimination half-life is 2.0-3.5 hours; prolonged to 6-12 hours in renal impairment.
After intrathecal administration, the terminal half-life of cytarabine in CSF is 2.5-4.5 hours (mean 3.5 hours) due to slow clearance from CSF; systemic half-life is 10-15 minutes due to rapid deamination.
Renal: 70-80% unchanged; Biliary/Fecal: 15-20%; minor hepatic metabolism.
Renal excretion of cytarabine metabolites accounts for >70% of elimination; unchanged cytarabine excretion is minimal (<10%). Biliary/fecal excretion is negligible (<5%).
Category C
Category C
Antineoplastic
Antineoplastic